Pediatric Ethics Subcommittee
Executive Summary
Ethics of a National Institutes of Health-supported protocol on leuprolide testing for puberty disorders to be reviewed by FDA's Pediatric Ethics Subcommittee Nov. 15. The protocol was rejected by University of Chicago Hospitals' Institutional Review Board because of risks from leuprolide (TAP's Lupron) to control subjects, FDA says in Oct. 7 1Federal Register notice calling for comments on the protocol. The meeting will be held at the Hilton in Gaithersburg, Md. beginning at 8:30 a.m...
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.